CD14 Controls the LPS-Induced Endocytosis of Toll-like Receptor 4

Slides:



Advertisements
Similar presentations
Differential effects of GLP-1 receptor agonist on foam cell formation in monocytes between non-obese and obese subjects  Masashi Tanaka, Yoshiyuki Matsuo,
Advertisements

Volume 72, Issue 2, Pages (July 2007)
Involvement of suppressors of cytokine signaling in toll-like receptor–mediated block of dendritic cell differentiation by Holger Bartz, Nicole M. Avalos,
Volume 9, Issue 5, Pages (November 1998)
Annexin A2 tetramer activates human and murine macrophages through TLR4 by Jennifer F. A. Swisher, Nicholas Burton, Silvia M. Bacot, Stefanie N. Vogel,
Takashi Tanaka, Michelle A. Soriano, Michael J. Grusby  Immunity 
Volume 25, Issue 6, Pages (December 2006)
Volume 31, Issue 1, Pages (July 2009)
Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients by Devi.
LPS induces CD40 gene expression through the activation of NF-κB and STAT-1α in macrophages and microglia by Hongwei Qin, Cynthia A. Wilson, Sun Jung Lee,
Volume 38, Issue 4, Pages (April 2013)
Volume 16, Issue 22, Pages (November 2006)
Volume 36, Issue 5, Pages (May 2012)
Volume 36, Issue 1, Pages (January 2012)
Volume 47, Issue 5, Pages e6 (November 2017)
Volume 19, Issue 6, Pages (September 2005)
Volume 127, Issue 5, Pages (November 2004)
Volume 26, Issue 5, Pages (May 2007)
Mechanisms of cross hyporesponsiveness to toll-like receptor bacterial ligands in intestinal epithelial cells  Jan-Michel Otte, Elke Cario, Daniel K.
Min Qin, Aslan Pirouz, Myung-Hwa Kim, Stephan R. Krutzik, Hermes J
Volume 47, Issue 4, Pages e3 (October 2017)
Volume 15, Issue 11, Pages (June 2016)
Volume 19, Issue 13, Pages (June 2017)
Volume 22, Issue 4, Pages (April 2005)
Volume 24, Issue 6, Pages (June 2006)
Min Qin, Aslan Pirouz, Myung-Hwa Kim, Stephan R. Krutzik, Hermes J
Volume 24, Issue 2, Pages (February 2006)
Volume 23, Issue 5, Pages (November 2005)
Daniel B. Stetson, Ruslan Medzhitov  Immunity 
An endogenous caspase-11 ligand elicits interleukin-1 release from living dendritic cells by Ivan Zanoni, Yunhao Tan, Marco Di Gioia, Achille Broggi, Jianbin.
Volume 37, Issue 6, Pages (December 2012)
Volume 34, Issue 3, Pages (March 2011)
Granulin Is a Soluble Cofactor for Toll-like Receptor 9 Signaling
Taro Kawai, Shizuo Akira  Immunity  Volume 34, Issue 5, Pages (May 2011)
C5a Negatively Regulates Toll-like Receptor 4-Induced Immune Responses
Volume 12, Issue 2, Pages (August 2012)
Caspase-8 Acts in a Non-enzymatic Role as a Scaffold for Assembly of a Pro- inflammatory “FADDosome” Complex upon TRAIL Stimulation  Conor M. Henry, Seamus.
Volume 22, Issue 2, Pages (February 2005)
TLR9 deficiency promotes aberrant T cell and myeloid dendritic cell (DC) phenotype in imiquimod-induced autoimmunity. TLR9 deficiency promotes aberrant.
Volume 19, Issue 5, Pages (November 2003)
Volume 19, Issue 3, Pages (September 2003)
Volume 27, Issue 2, Pages (August 2007)
Volume 30, Issue 2, Pages (February 2009)
Volume 14, Issue 2, Pages (August 2013)
Volume 32, Issue 5, Pages (May 2010)
Volume 44, Issue 3, Pages (March 2016)
Volume 38, Issue 3, Pages (March 2013)
Volume 32, Issue 4, Pages (April 2010)
Cell Type-Specific Involvement of RIG-I in Antiviral Response
Volume 12, Issue 6, Pages (December 2012)
Volume 15, Issue 2, Pages (February 2014)
Volume 9, Issue 5, Pages (May 2011)
Volume 12, Issue 4, Pages (October 2003)
Volume 4, Issue 6, Pages (December 2008)
Volume 21, Issue 6, Pages (November 2017)
Volume 33, Issue 5, Pages (November 2010)
Volume 72, Issue 2, Pages (July 2007)
IL-4 and IL-13 Alter Plasmacytoid Dendritic Cell Responsiveness to CpG DNA and Herpes Simplex Virus-1  Jurjen Tel, Ruurd Torensma, Carl G. Figdor, I.
Volume 22, Issue 6, Pages (February 2018)
Volume 150, Issue 3, Pages (August 2012)
Volume 6, Issue 2, Pages (August 2009)
Intestinal myofibroblasts in innate immune responses of the intestine
John M. Lamar, Vandana Iyer, C. Michael DiPersio 
Toll-Dependent Control Mechanisms of CD4 T Cell Activation
Volume 15, Issue 11, Pages (June 2016)
Volume 25, Issue 1, Pages e6 (October 2018)
Volume 24, Issue 1, Pages (January 2006)
Volume 156, Issue 4, Pages (February 2014)
Volume 28, Issue 1, Pages (January 2008)
Endogenous Control of Immunity against Infection: Tenascin-C Regulates TLR4- Mediated Inflammation via MicroRNA-155  Anna M. Piccinini, Kim S. Midwood 
Presentation transcript:

CD14 Controls the LPS-Induced Endocytosis of Toll-like Receptor 4 Ivan Zanoni, Renato Ostuni, Lorri R. Marek, Simona Barresi, Roman Barbalat, Gregory M. Barton, Francesca Granucci, Jonathan C. Kagan  Cell  Volume 147, Issue 4, Pages 868-880 (November 2011) DOI: 10.1016/j.cell.2011.09.051 Copyright © 2011 Elsevier Inc. Terms and Conditions

Cell 2011 147, 868-880DOI: (10.1016/j.cell.2011.09.051) Copyright © 2011 Elsevier Inc. Terms and Conditions

Figure 1 CD14 Is Required for LPS-Induced TLR4 Endocytosis (A and B) WT or CD14-deficient (KO) mouse BMDM (A) or DCs (B) were untreated or treated with LPS (1 μg/ml) for the times indicated. Flow cytometry was then used to examine receptor endocytosis by determining the surface levels of the endogenous proteins indicated. The third and fourth panels in (A) and (B) represent the mean fluorescence intensity (MFI) of specific receptor staining at each time point. (C and D) BMDM (C) or DCs (D) were treated with the concentrations of LPS indicated for 18 hr and the amounts of secreted cytokines were determined. (E and F) BMDM (E) or DCs (F) were treated with LPS (1 μg/ml) for the times indicated and the presence of active (dimerized) IRF3 in cell extracts was determined by native PAGE. See also Figure S1. Cell 2011 147, 868-880DOI: (10.1016/j.cell.2011.09.051) Copyright © 2011 Elsevier Inc. Terms and Conditions

Figure 2 The Natural Expression Profile of CD14 Determines which Cells Undergo LPS-Induced TLR4 Endocytosis (A) The cells indicated were examined for the expression of surface levels of endogenous CD14 by flow cytometry. (B) MEFs and A20 B cells were treated with LPS (1 μg/ml) for the times indicated and TLR4 endocytosis was monitored by flow cytometry. Shown are the MFI of specific TLR4 surface staining at each time point indicated. (C) A20 B cells were transiently transfected with a plasmid encoding CD14 and treated with LPS (1 μg/ml) for the times indicated before TLR4 endocytosis was examined by flow cytometry. (D) DCs, BMDM, or B cells were isolated from the spleen of mice and examined for the expression of surface levels of CD14 by flow cytometry. (E) Mice were injected with LPS (50 μg) and at the times indicated spleens were isolated and BMDM, DCs, and B cells were examined for surface levels of TLR4 by flow cytometry. (F) Splenic B cells were transfected with a plasmid encoding CD14 and treated for the indicated times with LPS (1 μg/ml) before TLR4 endocytosis was examined by flow cytometry. See also Figure S2. Cell 2011 147, 868-880DOI: (10.1016/j.cell.2011.09.051) Copyright © 2011 Elsevier Inc. Terms and Conditions

Figure 3 CD14 Is Required for LPS-Induced Macropinocytosis Macropinocytosis was measured in DCs (A) or BMDM (B) by flow cytometry. Cells were untreated or treated for the times indicated with fluorescent dextrans (1 mg/ml) in the presence or absence of LPS (1 μg/ml). Cell-associated fluorescence intensity was then compared between LPS-treated and untreated cell populations to determine changes from the steady state levels of macropinocytosis. Note that both CD14 and TLR4 are required for LPS-induced macropinocytosis. (C) MEFs or A20 B cells were untreated or treated for the times indicated with fluorescent dextrans (1 mg/ml) in the presence or absence of LPS (1 μg/ml). Cell associated fluorescence intensity was then compared between LPS-treated and untreated populations of cells to determine changes from the steady state levels of macropinocytosis. Cell 2011 147, 868-880DOI: (10.1016/j.cell.2011.09.051) Copyright © 2011 Elsevier Inc. Terms and Conditions

Figure 4 The CD14-Dependent Endocytosis Pathway Is Upregulated during DC Maturation (A) DCs were untreated or treated for 18 hr with CpG DNA (1 μM) or TNFα (100 pg/ml). DC maturation was then assessed by flow cytometry by determining the increase in surface staining of CD86, CD40, or MHC class II. (B) Immature DCs or DCs matured for 18 hr with CpG DNA (1 μM) or TNFα (100 pg/ml) were treated with LPS (1 μg/ml) and TLR4 endocytosis was measured by flow cytometry at the times indicated. Displayed are the MFIs of specific surface TLR4 staining at each time point. (C and D) Immature DCs or DCs matured for 18 hr with CpG DNA (1 μM) or TNFα (100 pg/ml) were treated with LPS at the concentrations indicated and the production of the indicated cytokines were measured after 18 hr. (E) DCs were either untreated or treated for 18 hr with CpG DNA (1μM) or TNFα (100 pg/ml) and the effect of these stimuli on the cell surface levels of CD14 was assessed by flow cytometry. (F) DCs of the genotypes indicated were processed as described in (E). After 18 hr, CD14 mRNA levels were determined by qPCR. (G) DCs were stimulated with the ligands indicated as described in (E) in the presence of absence of the NF-κB inhibitor Bay11-7085 and then processed to measure CD14 expression by qPCR. Cell 2011 147, 868-880DOI: (10.1016/j.cell.2011.09.051) Copyright © 2011 Elsevier Inc. Terms and Conditions

Figure 5 The Requirement of CD14 for TLR4 Endocytosis Can Be Bypassed with Phagocytic Cargo (A and B) The cells indicated were treated for the times indicated with fluorescent bacteria at a multiplicity of infection (MOI) of 10. Phagocytosis was then measured at each time point by determining the mean fluorescence intensity (MFI) of the cell populations by flow cytometry. (C) DCs were treated with E.coli at the MOIs indicated on the x axis, and the production of the indicated cytokines were measured after 18 hr. (D) DCs were treated with E.coli at an MOI of 10 or LPS (1 μg/ml) and TLR4 endocytosis was measured by flow cytometry at the times indicated. Displayed are the MFIs of specific surface TLR4 staining at each time point. (E) BMDM were treated with E.coli at the MOIs indicated on the x axis, and the production of the cytokines indicated were measured. (F) BMDM were treated with E.coli at an MOI of 10 or LPS (1 μg/ml) and TLR4 endocytosis was measured by flow cytometry at the times indicated. Displayed are the MFIs of specific surface TLR4 staining at each time point. (G) DCs were treated with either LPS-coated latex beads or uncoated beads and the production of the cytokines indicated were measured. (H) DCs were treated with either LPS-coated latex beads or uncoated beads in the presence of soluble LPS and TLR4 endocytosis was measured by flow cytometry at the times indicated. Displayed are the MFIs of specific surface TLR4 staining at each time point. See also Figure S3. Cell 2011 147, 868-880DOI: (10.1016/j.cell.2011.09.051) Copyright © 2011 Elsevier Inc. Terms and Conditions

Figure 6 Role of Syk and PLCγ2 in Regulating the CD14-Dependent Endocytosis of TLR4 (A) Immortal BMDM or primary macrophages and DCs of the genotypes indicated were either untreated or treated with LPS (1 μg/ml) for the times indicated. Flow cytometry was then used to examine receptor endocytosis by determining the surface levels of the endogenous TLR4. Shown are the MFIs of specific TLR4 surface staining at each time point indicated. (B and C) BMDM (B) or DCs (C) of the genotypes indicated were treated with 10 ng/ml LPS for the times indicated and the rate of TLR4 endocytosis was assessed by flow cytometry (first panel). Second and third panels: cells were stimulated with 10 ng/ml LPS for 18 hr and the amounts of secreted cytokines were determined. (D) The cells indicated were treated with the Src inhibitor in the presence or absence of LPS (10 ng/ml) and the rate of TLR4 endocytosis was monitored by flow cytometry. (E) BMDM were treated with the Syk inhibitor piceatannol (75 μM) and were then stimulated with 10 ng/ml LPS. At the times indicated, the rate of TLR4 endocytosis was assessed by flow cytometry (first panel). Second and third panels: cells were stimulated in the presence or absence of piceatannol with 10 ng/ml LPS for 18 hr, and the amounts of secreted cytokines were determined. Fourth panel: BMDM were treated with LPS (1 μg/ml) for 30 min in the presence or absence of piceatannol (75 μM). The presence of dimerized IRF3 and IκBα was assessed by western analysis. (F) BMDM of the genotypes indicated were treated with 10 ng/ml LPS for either 30 or 90 min. The rate of TLR4 endocytosis was assessed by flow cytometry (first panel). Second and third panels: cells were stimulated with 10 ng/ml LPS for 18 hr, and the amounts of secreted cytokines were determined. See also Figure S4. Cell 2011 147, 868-880DOI: (10.1016/j.cell.2011.09.051) Copyright © 2011 Elsevier Inc. Terms and Conditions

Figure 7 Syk Is Activated by LPS by a Process Dependent on CD14 but Independent of TLR4 (A) BMDM of the genotypes indicated were stimulated with LPS (100 ng/ml). At the times indicated, the presence of phospho-Syk was examined by western blot. (B) BMDM and DCs of the genotypes indicated were stimulated with either LPS or curdlan and the presence of phospho-Syk was detected by flow cytometry. (C) BMDM were stimulated with LPS (100 ng/ml) for the times indicated and processed for confocal microscopy to detect the presence of CD14, Cholera Toxin B (CTB) or dextran loaded lysosomes. All images for all panels are representative of at least three independent experiments where over 500 cells were examined per condition and > 95% of the cells displayed similar staining. (D) Model depicting a cascade of transport events that is mediated by CD14 in order to promote TLR4 signaling. CD14 first captures and transports LPS to the plasma membrane localized complex of TLR4 and MD2, which signals through the TIRAP-MyD88 adaptors to activate inflammatory cytokine expression. CD14 then transports TLR4 to endosomes by a process mediated by Syk and PLCγ2, where TRAM-TRIF signaling can lead to the expression of IFNs. See also Figure S5. Cell 2011 147, 868-880DOI: (10.1016/j.cell.2011.09.051) Copyright © 2011 Elsevier Inc. Terms and Conditions

Figure S1 CD14 Is Not Essential for TLR4 Signaling from the Plasma Membrane, Related to Figure 1 (A) DCs were left untreated or treated with LPS (1 μg/ml) for 30 min and the complex of MyD88 and IRAK4 was examined by western blot. DCs (B) or BMDM (C) were treated with LPS (1μg/ml). At the times indicated, MyD88-dependent changes in IκB levels, p-p38, and p-ERK1/2 were examined by western blot. (D) Immortalized BMDM were stimulated with the ligands indicated. At either 3 or 6 hr posttreatment, the expression of IL-6 or Viperin was examined by qPCR. (E) Inflammatory monocytes were stimulated with either CpG DNA or Vaccinia Virus at the multiplicity of infection (MOI) indicated. The induction of TLR9 or TLR2 dependent IFN was then assessed using a bioassay as described (Barbalat et al., 2009). Cell 2011 147, 868-880DOI: (10.1016/j.cell.2011.09.051) Copyright © 2011 Elsevier Inc. Terms and Conditions

Figure S2 CD14 Expression Levels in DCs and BMDM, Related to Figure 2 (A) CD14 surface staining was determined by flow cytometry in BMDM and DCs derived from WT and TLR4-deficient (KO) mice. (B) A20 B cells were treated with LPS (1 μg/ml) for 24 hr and the increase in MHC class II and CD69 was examined by flow cytometry. Cell 2011 147, 868-880DOI: (10.1016/j.cell.2011.09.051) Copyright © 2011 Elsevier Inc. Terms and Conditions

Figure S3 DCs, but Not BMDM, Permit the Nonspecific Entry of FcγR1 into Cells during Phagocytosis, Related to Figure 5 (A) DCs or BMDM of the genotypes indicated were treated with uncoated latex beads and at the times indicated, the surface staining of FcγR1 was assessed by flow cytometry. Displayed are the MFIs of specific surface FcγR1 staining at each time point. Cell 2011 147, 868-880DOI: (10.1016/j.cell.2011.09.051) Copyright © 2011 Elsevier Inc. Terms and Conditions

Figure S4 Chemical Inhibitors of PLC and Syk Disrupt TLR4 Endocytosis and Signaling, Related to Figure 6 (A) BMDM and DCs of the genotypes indicated were untreated or treated with LPS (10 ng/ml) for the times indicated. Flow cytometry was then used to examine receptor endocytosis by determining the surface levels of the endogenous TLR4. Shown are the MFIs of specific TLR4 surface staining at each time indicated. Note, similar results were obtained with LPS doses as high as 1μg/ml. (B and C) BMDM (B) or DCs (C) were treated with 10ng/ml LPS for the times indicated in the presence or absence of the PLC inhibitor U73122. The rate of TLR4 endocytosis was assessed by flow cytometry (first panel). Second and third panels, cells were stimulated with 10ng/ml LPS for 18 hr and the amounts of secreted cytokines were determined. (D and E) Exactly as described for (B) and (C), except the cells with treated with the Syk inhibitor Bay61-3606. Cell 2011 147, 868-880DOI: (10.1016/j.cell.2011.09.051) Copyright © 2011 Elsevier Inc. Terms and Conditions

Figure S5 LPS-Induced CD14 Endocytosis Proceeds by a Pathway Similar to That Taken by TLR4, Related to Figure 7 (A) DCs were treated with the Syk inhibitor piceatannol (75 μM) and were then stimulated with 10 ng/ml LPS. At the times indicated, the rate of TLR4 endocytosis was assessed by flow cytometry (first panel). Second and third panels, cells were stimulated in the presence or absence of piceatannol with 10 ng/ml LPS for 18 hr and the amounts of secreted cytokines were determined. Fourth panel, DCs were treated with LPS (1 μg/ml) for 30 min in the presence or absence of piceatannol (75 μM). The presence of dimerized IRF3 and IκBα was assessed by western analysis. (B) DCs of the genotypes indicated were treated with 10 ng/ml LPS for either 30 or 90 min. The rate of TLR4 endocytosis was assessed by flow cytometry (first panel). Second and third panels, cells were stimulated with 10 ng/ml LPS for 18 hr and the amounts of secreted cytokines were determined. (C) Mice were injected with LPS (50 μg) and at the times indicated spleens were isolated and macrophages and DCs were examined for surface levels of CD14 by flow cytometry. Shown are the MFIs of CD14 surface staining at each time point indicated. (D and E) DCs (D) or BMDM (E) of the genotypes indicated were treated with 10ng/ml LPS for the times indicated in the presence or absence of the Syk inhibitor piceatannol (75 μM). The rate of CD14 endocytosis was assessed by flow cytometry. (F) BMDM were stimulated with LPS (100ng/ml) for the times indicated and processed for confocal microscopy to detect the presence of CD14 or EEA1. All images for all panels are representative of at least three independent experiments where over 500 cells were examined per condition and >95% of the cells displayed similar staining. Cell 2011 147, 868-880DOI: (10.1016/j.cell.2011.09.051) Copyright © 2011 Elsevier Inc. Terms and Conditions